阿瑞匹坦对胃轻瘫及相关疾病患者恶心症状的混合效应及其他症状的改善作用
一项为期4周的多中心双盲随机试验纳入126例胃轻瘫或类胃轻瘫综合征所致慢性恶心呕吐患者,阿瑞匹坦组(125 mg/日,n=63)与安慰剂组(n=63)在主要结局(恶心VAS评分降低≥25 mm或绝对值<25 mm)上无显著差异(46% vs 40%,RR 1.2,95%CI 0.8-1.7,P=0.43)。但阿瑞匹坦组在恶心、呕吐及总体症状严重程度等次要结局上改善更显著,不良事件更常见(35% vs 17%,P=0.04)。
要点
- 阿瑞匹坦未显著改善主要结局指标恶心的VAS评分应答率(46% vs 40%,RR 1.2,95%CI 0.8-1.7,P=0.43)。
- 阿瑞匹坦组恶心、呕吐及总体症状严重程度(0-5分胃轻瘫临床症状指数)下降幅度均显著大于安慰剂组。
- 阿瑞匹坦组不良事件更常见(22/63,35% vs 11/63,17%,P=0.04),以轻中度为主。
核心结论
- 在胃轻瘫或类胃轻瘫综合征所致慢性恶心呕吐患者中,以VAS评分降低为主要结局时,阿瑞匹坦未减轻恶心严重程度。
- 阿瑞匹坦对次要结局的症状改善有不同程度的效应。
- 这些发现支持需要为胃轻瘫治疗试验确定合适的患者结局指标,包括可能针对阿瑞匹坦的进一步试验。
研究设计与样本
- 4周多中心双盲随机试验,纳入126例慢性恶心呕吐(推测胃源性)至少中度症状持续至少6个月的患者。
- 患者随机接受口服阿瑞匹坦125 mg/日(n=63)或安慰剂(n=63)。
- 主要结局采用意向性治疗分析,定义为每日患者报告的0-100视觉模拟量表(VAS)恶心严重程度降低≥25 mm或绝对值<25 mm。
- 采用分层Cochran-Mental-Haenszel分析计算恶心改善的相对危险度。
主要发现
- 主要结局:阿瑞匹坦组VAS评分降低46% vs 安慰剂组40%,相对危险度1.2(95%CI 0.8-1.7),P=0.43。
- 次要结局(0-5分胃轻瘫临床症状指数)恶心严重程度降低:阿瑞匹坦组1.8 vs 安慰剂组1.0,P=0.005。
- 次要结局呕吐严重程度降低:阿瑞匹坦组1.6 vs 安慰剂组0.5,P=0.001。
- 次要结局总体症状降低:阿瑞匹坦组1.3 vs 安慰剂组0.7,P=0.001。
- 不良事件:阿瑞匹坦组22/63(35%) vs 安慰剂组11/63(17%),P=0.04,以轻中度为主。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: There are few effective treatments for nausea and other symptoms in patients with gastroparesis and related syndromes. We performed a randomized trial of the ability of the neurokinin-1 receptor antagonist aprepitant to reduce symptoms in patients with chronic nausea and vomiting caused by gastroparesis or gastroparesis-like syndrome. METHODS: We conducted a 4-week multicenter, double-masked trial of 126 patients with at least moderate symptoms of chronic nausea and vomiting of presumed gastric origin for a minimum of 6 months. Patients were randomly assigned to groups given oral aprepitant (125 mg/day, n = 63) or placebo (n = 63). The primary outcome from the intention-to-treat analysis was reduction in nausea, defined as a decrease of 25 mm or more, or absolute level below 25 mm, on a daily patient-reported 0-to-100 visual analog scale (VAS) of nausea severity. We calculated relative risks of nausea improvement using stratified Cochran-Mental-Haenszel analysis. RESULTS: Aprepitant did not reduce symptoms of nausea, based on the primary outcome measure (46% reduction in the VAS score in the aprepitant group vs 40% reduction in the placebo group; relative risk, 1.2; 95% CI, 0.8-1.7) (P = .43). However, patients in the aprepitant group had significant changes in secondary outcomes such as reduction in symptom severity (measured by the 0-5 Gastroparesis Clinical Symptom Index) for nausea (1.8 vs 1.0; P = .005), vomiting (1.6 vs 0.5; P = .001), and overall symptoms (1.3 vs 0.7; P = .001). Adverse events, predominantly mild or moderate in severity grade, were more common in aprepitant (22 of 63 patients, 35% vs 11 of 63, 17% in the placebo group) (P = .04). CONCLUSIONS: In a randomized trial of patients with chronic nausea and vomiting caused by gastroparesis or gastroparesis-like syndrome, aprepitant did not reduce the severity of nausea when reduction in VAS score was used as the primary outcome. However, aprepitant had varying effects on secondary outcomes of symptom improvement. These findings support the need to identify appropriate patient outcomes for trials of therapies for gastroparesis, including potential additional trials for aprepitant. ClinicalTrials.gov no: NCT01149369.
引用
- Pasricha PJ, Yates KP, Sarosiek I, et al. Aprepitant Has Mixed Effects on Nausea and Reduces Other Symptoms in Patients With Gastroparesis and Related Disorders. Gastroenterology. 2017. PMID: 29111115. doi:10.1053/j.gastro.2017.08.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。